Hycamptin
Ovarian Cancer
Hellenic Oncology Research GroupPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 59/ 100
Competitive context
525 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
TIL Inge Marie Svane | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Kalinski, Pawel, MD, PhD | Phase 3 | BB |
OTL-38 On Target Laboratories, LLC | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →